Form 4: KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, sold 1,963 shares to cover tax obligations following the vesting of restricted stock units.
Summary
- Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, engaged in transactions involving the company's common stock.
- On November 22, 2024, 3,125 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of common stock.
- Following the vesting, Mr. Yea sold 1,963 shares on November 26, 2024, at a weighted average price of $9.8718 per share.
- The sale was to cover tax withholding obligations associated with the vesting of the RSUs and was not a discretionary transaction.
- The price of the shares sold ranged from $9.87 to $9.99 per share.
- After these transactions, Mr. Yea directly owns 91,142 shares of common stock and 43,750 RSUs.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.
Comparison to Industry Standards
- The sale of shares to cover tax obligations upon vesting of restricted stock units is a standard practice across publicly traded companies.
- Many biotechnology companies use RSUs as part of their executive compensation packages, similar to KalVista Pharmaceuticals.
- The price range of $9.87 to $9.99 per share is within the typical range for stock sales related to tax obligations.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.
Key Dates
| Date | Description |
|---|---|
| 11/22/2024 | Restricted stock units (RSUs) vested. |
| 11/26/2024 | Shares sold to cover tax obligations. |
| 11/27/2024 | Date of filing of the Form 4. |
Keywords
KalVista Pharmaceuticals, Christopher Yea, restricted stock units, RSU, stock sale, tax obligations, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.